Your Health, We Care
In 2001, Stiripentol was recognized as an "orphan drug" by the European Union for its use in severe myoclonic epilepsy (SMEI) in infants.
In the international consensus on the diagnosis and treatment of Dravet syndrome (DS), Stiripentol is considered one of the second-line treatment drugs, reflecting its important position in the international field of antiepileptic drugs.
Dravet syndrome is a rare and refractory epileptic encephalopathy, and Stiripentol is widely used to improve the seizure status of patients by inhibiting the hepatocytochrome P450 ···【more】
Article source：Lucius LaosRelease date：2024-08-28Recommended：158
Stiripentol is an innovative antiepileptic drug used to treat Dravet syndrome, mainly by enhancing GABAergic nerve conduction and reducing the frequency of seizures in patients. In···【more】
Article source：Lucius LaosRelease date：2024-08-28Recommended：142
Stipentol is an anti-epileptic drug that reduces seizures primarily by boosting the GABA system in the brain. By stabilizing the excitability of neurons, the frequency of seizures ···【more】
Article source：Lucius LaosRelease date：2024-08-27Recommended：121
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
